Obtén las últimas noticias y titulares bursátiles de Alpine Immune Sciences, Inc. (ALPN) para ayudarte en tus decisiones de operaciones e inversiones. Alpine Immune Sciences Announces Preclinical Data from ALPN-101 Program Demonstrating Efficacy in Humanized Model of Graft Versus Host Disease — Data Presented at 59th American Society of Hematology Annual Meeting & Exposition — SEATTLE, December 9, 2017 – Alpine… Detailed price information for Alpine Immune Sciences Inc (ALPN-Q) from The Globe and Mail including charting and trades. ... About Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, … The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancies Business Wire • 5 months ago Alpine Immune Sciences and … Find out more about how we use your information in our Privacy Policy and Cookie Policy. We completed enrollment in the first human clinical trial of ALPN-101, our first-in-class dual CD28/ICOS antagonist in October 2019. Information about your device and Internet connection, including your IP address, Browsing and search activity while using Verizon Media websites and apps. Alpine Immune Sciences is a Seattle-based company founded in 2015. About Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc. was founded in 2015 and is focused on developing novel protein‐based immunotherapies using its proprietary variant immunoglobulin domain (vIgD™) platform technology. Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2019. Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release third quarter 2020 financial results on Thursday, November 12, 2020 after the close of market. See Alpine Immune Sciences's revenue, employees, and funding info on Owler, the world’s largest community-based … Our vIgD platform creates molecules which can be formatted in many different ways, including standard Fc fusion proteins, localized Fc fusion proteins, and monoclonal antibody fusion proteins as well as formulated as a Transmembrane Immunomodulatory Protein (“TIP™”) or as a Secreted Immunomodulatory Protein (“SIP™”). Find the latest press releases from Alpine Immune Sciences, Inc. Common Stock (ALPN) at Nasdaq.com. All Rights Reserved, Alpine Immune Sciences Inc. SEATTLE --(BUSINESS WIRE)--Mar. 10, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the planned presentation of two posters at the American, SEATTLE --(BUSINESS WIRE)--Feb. 22, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will participate at the Cowen 41st Annual, Alpine Immune Sciences to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update, Alpine Immune Sciences Announces Poster Presentations at AACR Virtual Annual Meeting I, Alpine Immune Sciences to Participate in Upcoming Virtual Healthcare Conferences. Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, … © 2021 Alpine Immune Sciences. Alpine is a clinical-stage specialty pharmaceutical company focused on discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer and autoimmune/inflammatory diseases. ALPN-202, our conditional CD28 costimulator and dual checkpoint inhibitor, is expected to begin Phase 1 trials in cancer patients in 2020. Contact: Paul Rickey, Chief Financial Officer Alpine Immune Sciences, Inc. 206-788-4545 ir@alpineimmunesciences.com. Alpine Immune Sciences, Inc: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Press Release Dec 11, 2020 13:00 UTC. 11, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release fourth quarter and full year, SEATTLE --(BUSINESS WIRE)--Mar. Alpine has two lead programs. SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced positive results from multiple preclinical studies which were presented at the American Society of Hematology's (ASH) 60th Annual Meeting & Exposition in San Diego, CA. Alpine Immune Sciences Announces Executive Leadership Addition and Promotion Pamela Holland, Ph.D., Joins as Senior Vice President, Research Remy Durand, Ph.D., Promoted to … We and our partners will store and/or access information on your device through the use of cookies and similar technologies, to display personalised ads and content, for ad and content measurement, audience insights and product development. Press Release Mar 10, 2021 21:30 UTC. Alpine Immune Sciences Announces Poster Presentations at AACR Virtual Annual Meeting I SEATTLE--(Business Wire)--Alpine Immune Sciences… To enable Verizon Media and our partners to process your personal data select 'I agree', or select 'Manage settings' for more information and to manage your choices. ALPINE IMMUNE SCIENCES, INC. : Press releases relating to ALPINE IMMUNE SCIENCES, INC. Investor relations | Nasdaq: ALPN | Nasdaq You can change your choices at any time by visiting Your privacy controls. Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release fourth quarter and full year 2020 financial results on Thursday, March 18, 2021 after the close of market. Yahoo is part of Verizon Media. SEATTLE --(BUSINESS WIRE)--Feb. 22, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will participate at … ET Get the latest Alpine Immune Sciences, Inc. (ALPN) stock news and headlines to help you in your trading and investment decisions. Alpine Immune Sciences Announces $60 Million Private Placement. ‘BALANCE’, a Phase 1b/2 clinical trial in acute GVHD is expected to begin enrollment in 2020. SEATTLE--(BUSINESS WIRE)--Jan. 16, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company dedicated to developing innovative treatments for patients suffering from cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities purchase agreement for the sale of units consisting of shares of common stock and … Press Release Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors Published: Dec. 11, 2020 at 8:00 a.m. 188 East Blaine Street Suite 200 Seattle, WA 98102 206-788-4545 Our proprietary Variant Immunoglobulin Domain™ (“vIgD™”) scientific platform uses a process known as directed evolution to create therapeutics potentially capable of modulating human immune system proteins. The first, ALPN-101 for autoimmune/inflammatory diseases, is a dual ICOS/CD28 antagonist, engineered to reduce pathogenic immune responses. Laurence Watts, Managing Director Gilmartin Group, LLC. Alpine Immune Sciences creates modern therapies targeting the immune synapse to treat cancer and autoimmune disease. Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities purchase agreement for the sale of common units and prefunded warrant units, as described below, in a private placement with certain … Alpine Immune Sciences Inc. 188 East Blaine Street Suite 200 Seattle, WA 98102 206-788-4545 Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release second quarter 2020 financial results on Tuesday, August 11, 2020 after the close of market.